Abstract
Function of astroglia in the modulation of availability, release and clearance (inactivation) of Glu and GABA within the central nervous system is reviewed. Net synthesis of Glu through Gln synthethase exclusively localized in astrocytes can only occur by a metabolic coupling between neurons and astrocytes. Two (GLAST and GLT-1) of the five Glu transporters cloned preferentially expressed in astrocytes perform the astroglial Glu uptake of very high capacity. Moreover, astrocytes have been shown to mediate Glu release by a mechanism mimicking vesicular release. Biosynthesis of GABA in neurons is brought about by decarboxylation of Glu catalyzed by a pyridoxal phosphate requiring enzyme (GAD) that exists in two isoforms (GAD65 and GAD67) exhibiting different subcellular localization and regulatory properties. Detailed studies of GABA synthesis in GABAergic neurons using 13C NMR spectroscopy have provided evidence for direct involvement of the tricarboxylic acid cycle. Synaptically released GABA taken up into surrounding astrocytes is converted to either CO2 or Gln. Two reports on the release of GABA in rat dorsal root ganglia indicated that glial cells may perform GABA release as well. Gln formed from GABA in astrocytes can be transferred to GABAergic neurons and subsequently converted to GABA. Inhibition of either degradation or clearance of GABA has been successfully applied in the development of antiepileptics such as vigabatrin or tiagabine. So far, no specific strategy has been developed aimed at stimulating Glu transport.
Keywords: Metabolic coupling between neurons and astrocytes, GABA-Glu-Gln cycle, GLAST, GLT-1, tiagabine, BGT- 1/GAT2 inhibitor EF 1502
Current Topics in Medicinal Chemistry
Title: Glial Modulation of GABAergic and Glutamat ergic Neurotransmission
Volume: 6 Issue: 10
Author(s): Arne Schousboe and Helle S. Waagepetersen
Affiliation:
Keywords: Metabolic coupling between neurons and astrocytes, GABA-Glu-Gln cycle, GLAST, GLT-1, tiagabine, BGT- 1/GAT2 inhibitor EF 1502
Abstract: Function of astroglia in the modulation of availability, release and clearance (inactivation) of Glu and GABA within the central nervous system is reviewed. Net synthesis of Glu through Gln synthethase exclusively localized in astrocytes can only occur by a metabolic coupling between neurons and astrocytes. Two (GLAST and GLT-1) of the five Glu transporters cloned preferentially expressed in astrocytes perform the astroglial Glu uptake of very high capacity. Moreover, astrocytes have been shown to mediate Glu release by a mechanism mimicking vesicular release. Biosynthesis of GABA in neurons is brought about by decarboxylation of Glu catalyzed by a pyridoxal phosphate requiring enzyme (GAD) that exists in two isoforms (GAD65 and GAD67) exhibiting different subcellular localization and regulatory properties. Detailed studies of GABA synthesis in GABAergic neurons using 13C NMR spectroscopy have provided evidence for direct involvement of the tricarboxylic acid cycle. Synaptically released GABA taken up into surrounding astrocytes is converted to either CO2 or Gln. Two reports on the release of GABA in rat dorsal root ganglia indicated that glial cells may perform GABA release as well. Gln formed from GABA in astrocytes can be transferred to GABAergic neurons and subsequently converted to GABA. Inhibition of either degradation or clearance of GABA has been successfully applied in the development of antiepileptics such as vigabatrin or tiagabine. So far, no specific strategy has been developed aimed at stimulating Glu transport.
Export Options
About this article
Cite this article as:
Schousboe Arne and Waagepetersen S. Helle, Glial Modulation of GABAergic and Glutamat ergic Neurotransmission, Current Topics in Medicinal Chemistry 2006; 6 (10) . https://dx.doi.org/10.2174/156802606777323719
DOI https://dx.doi.org/10.2174/156802606777323719 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Understanding the Molecular Mechanisms of Betel miRNAs on Human
Health
MicroRNA A Review of Lysergic Acid Diethylamide (LSD) in the Treatment of Addictions: Historical Perspectives and Future Prospects
Current Drug Abuse Reviews Recent Patents on Light Based Therapies: Photodynamic Therapy, Photothermal Therapy and Photoimmunotherapy
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Whole Embryo Culture: An Important Tool in Developmental Toxicology Today
Current Pharmaceutical Design Characterization of a New Positive Allosteric Modulator of AMPA Receptors - PAM-43: Specific Binding of the Ligand and its Ability to Potentiate AMPAR Currents
Current Molecular Pharmacology Molecular Properties Prediction, Docking Studies, and Antimicrobial Screening of 1,3,4-Thiadiazole and s-Triazole Derivatives
Current Computer-Aided Drug Design synthesis and Structure-Activity Relationships of 2,3-Benzodiazepines as AMPA Receptor Antagonists
Mini-Reviews in Medicinal Chemistry GABAB Receptors as Potential Therapeutic Targets
Current Drug Targets - CNS & Neurological Disorders Update on Medical and Surgical Management of Intracerebral Hemorrhage
Reviews on Recent Clinical Trials Novel Indications for Benzodiazepine Antagonist Flumazenil in GABA Mediated Pathological Conditions of the Central Nervous System
Current Pharmaceutical Design Editorial [Hot Topic: ABC Transporters in Pharmacology/Physiology and Human Diseases (Guest Editor: Zhe-Sheng (Jason) Chen)]
Current Pharmaceutical Biotechnology The Multiple Roles of Vitamin D in Human Health. A Mini-Review
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Deep Brain Stimulation for Alzheimer’s Disease
Current Alzheimer Research Anti-Tumor Effects of Osthole on Different Malignant Tissues: A Review of Molecular Mechanisms
Anti-Cancer Agents in Medicinal Chemistry From Blood-to-Brain: Regulating the Permeability of the Blood-Brain Barrier
Current Psychopharmacology New Prospects for the Drug Treatment of Generalized Anxiety Disorder — A Systematic Review
Current Drug Therapy The Interaction Potential of Retigabine (Ezogabine) with Other Antiepileptic Drugs
Current Clinical Pharmacology Pharmacotherapy of Borderline Personality Disorder: A Systematic Review
Current Medicinal Chemistry Triggers of Cell Death in the Developing Brain
Current Pediatric Reviews Review of Somnambulism in Children
Current Pediatric Reviews